The medical device maker flagged that an Aug. 25 cyber incident disrupting global operations now jeopardizes the net sales growth and adjusted profit targets it had set for the current quarter and the full year, with shares sliding in premarket trading.
Boston Scientific said a cyberattack that disrupted its manufacturing and order shipments across the globe will materially cut its third-quarter and full-year 2026 sales and profit, a warning that sent the medical device maker's shares down 4.5% in premarket trading on Tuesday.
"The attack on Boston Scientific demonstrates that cyber incidents in the medtech sector extend far beyond IT and actively threaten the global healthcare supply chain," Dray Agha, senior manager of security operations at cybersecurity firm Huntress, said.
The company, an S&P 500 constituent, said it is unlikely to meet the net sales growth and adjusted earnings-per-share forecasts it issued before the incident, which it discovered on Aug. 25 and disclosed the same day in a Form 8-K filed with the U.S. Securities and Exchange Commission. Boston Scientific said the disruption had hindered its ability to process and ship customer orders, and that the full scope, nature and financial impact were still being determined.
In a Sept. 5 update, Boston Scientific said it had seen no indication of unauthorized activity in its environment since the attack and that the impact appeared isolated to select internal infrastructures. The company said its distribution network had been "substantially restored," with major distribution centers processing and shipping products at or above normal operating levels, all sterilisation facilities operational and manufacturing resumed across most facilities globally. Teams are working around the clock to clear backlogs and speed delivery to patients, it said.
The warning lands as cyberattacks have become a recurring threat to medical device makers. Stryker and Intuitive Surgical both disclosed incidents in March, evidence of a sector whose production of devices relied on in hospitals and surgical suites can stall when a single system goes dark.
For Boston Scientific, the stakes are the growth trajectory it had mapped for 2026. The company had been expanding across cardiovascular, endoscopy and neuromodulation lines, and the outage now threatens the revenue and margin targets tied to that pipeline. Investors will watch the next earnings disclosure for the size of the shortfall and how quickly the order backlog can be rebuilt.
The incident also tests operational resilience across the broader medtech sector, where just-in-time supply chains leave little buffer when a distribution hub or plant stops shipping. Rivals that escaped the disruption could capture share in the interim, though the medical device market's long procurement cycles mean any shift is likely to be gradual.
Boston Scientific did not disclose a revised dollar figure for the expected impact, saying its materiality assessment was ongoing. Its next scheduled earnings report will show whether the third-quarter hit is contained or spills further into 2026.
This article is for informational purposes only and does not constitute investment advice.
